In vivo最新文献

{"title":"B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis.","authors":"Ece Akbayir, Tugce Kizilay, Ruziye Erol, Duygu Ozkan-Yasargun, Erdem Tuzun, Vuslat Yilmaz, Recai Turkoglu","doi":"10.21873/invivo.13920","DOIUrl":"10.21873/invivo.13920","url":null,"abstract":"<p><strong>Background/aim: </strong>Ocrelizumab, a CD20-targeting monoclonal antibody, is used for treatment of multiple sclerosis. The aim of this study was to explore the utility of peripheral blood cell subsets in prediction of treatment response to ocrelizumab in relapsing remitting multiple sclerosis (RRMS).</p><p><strong>Patients and methods: </strong>Thirty-one patients with RRMS resistant to first-line immunomodulating agents were enrolled and followed-up for 12 months under ocrelizumab treatment. Disease activity was monitored by 6-monthly assessments of Expanded Disability Status Scale and cranial-spinal magnetic resonance imaging. No evidence of disease activity (NEDA-3) status was determined, and peripheral blood mononuclear cells were immunophenotyped by flow cytometry.</p><p><strong>Results: </strong>Peripheral blood populations of CD19⁺ B-cells, plasma cells and CD3⁺ CD20⁺ T-cells decreased under ocrelizumab therapy, whereas populations of switched memory B-cells, CD4⁺ T-cells, naïve T-cells and regulatory B-1a and CD49d⁺ T-cells were increased. NEDA-3 status was achieved by 19 patients, who exhibited elevated baseline populations of regulatory CD49d⁺ T- and B-1a-cells, reduced post-treatment (month 6 or 12) populations of switched memory B-cells, and increased post-treatment populations of naïve T-cells. Month 12 Expanded Disability Status Scale scores correlated positively with plasmablast and naïve T-cell populations.</p><p><strong>Conclusion: </strong>Response to ocrelizumab is linked to baseline regulatory and post-treatment effector B- and T-cell subset populations. Memory B-cells appear to be a marker of treatment efficacy for ocrelizumab.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1162-1172"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New-onset Bipolar Disorder in Hidradenitis Suppurativa Patients: A Multi-center, Propensity-score-matched Cohort Study.","authors":"Meng-Che Wu, Yun-Feng Li, Chen-Yu Lin, Nung-Hsiang Lin, Chien-Ying Lee, Yu-Jung Su, Hui-Chin Chang, Shuo-Yan Gau","doi":"10.21873/invivo.13911","DOIUrl":"10.21873/invivo.13911","url":null,"abstract":"<p><strong>Background/aim: </strong>Hidradenitis suppurativa (HS) may be linked to an elevated risk of bipolar disorder, though the precise mechanism remains unclear. This study investigated the likelihood of bipolar disorder in patients with HS.</p><p><strong>Patients and methods: </strong>We analyzed the electronic health records of 60,850 patients with HS and 60,850 matched controls from the TriNetX network, excluding those with a prior bipolar disorder diagnosis. Propensity score matching was conducted (1:1 ratio), and hazard ratios (HRs) were calculated to assess the risk of new-onset bipolar disorder in patients with HS compared to controls.</p><p><strong>Results: </strong>After matching, the HR for developing bipolar disorder in patients with HS was 1.549 [95% confidence interval (CI)=1.270-1.889] after a 1-year follow-up, remaining significant in 3- and 5-year follow-ups and sensitivity analyses. Stratified by sex, female patients with HS showed a notably higher risk (HR=1.509, 95%CI=1.353-1.683), while no significant increase was seen in males.</p><p><strong>Conclusion: </strong>Patients with HS have a significantly elevated risk of developing bipolar disorder, especially among females. Healthcare providers should be mindful of this association when treating patients with HS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1067-1077"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Newly Installed Spot Scanning Proton Beam Therapy for Prostate Cancer.","authors":"Sachika Shiraishi, Yukiyasu Horikawa, Ryota Umeda, Kazuki Matsumoto, Akihiro Yamano, Masashi Yamanaka, Takahiro Shimo, Taro Murai, Ichiro Miura, Koichi Tokuuye","doi":"10.21873/invivo.13888","DOIUrl":"10.21873/invivo.13888","url":null,"abstract":"<p><strong>Background/aim: </strong>This study aimed to analyse retrospectively the initial treatment outcomes and associated toxicities of a spot scanning proton beam therapy for prostate cancer at the Shonan-Kamakura General Hospital.</p><p><strong>Patients and methods: </strong>A laterally opposing single-field uniform dose of spot-scanning proton beam was used. The doses were determined to be 60 Gy in 20 fractions for low-risk prostate cancer and 63 Gy in 21 fractions for intermediate- and high-risk prostate cancers. Genitourinary (GU) and gastrointestinal (GI) toxicities were also evaluated. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</p><p><strong>Results: </strong>A total of 135 patients were treated over two years, 51 of whom underwent hydrogel spacer insertion. During the limited observation period, no patient experienced a recurrence. Grade 2 GU toxicities were observed in 17 patients, whereas grade 1 or greater GI toxicities were observed in seven patients. None of the patients in whom a hydrogel spacer was inserted experienced grade 1 or higher GI toxicity.</p><p><strong>Conclusion: </strong>Proton beam therapy is safe for the treatment of prostate cancer. The insertion of a gold marker and hydrogel spacer led to a reduction in the rectal radiation dose and GI toxicity.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"851-858"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing.","authors":"Nobuki Furubayashi, Manabu Mochida, Atsuhiro Kijima, Yushi Fujimoto, Motonobu Nakamura, Takahito Negishi","doi":"10.21873/invivo.13903","DOIUrl":"10.21873/invivo.13903","url":null,"abstract":"<p><strong>Background/aim: </strong>The efficacy and safety of avelumab according to age, performance status (PS), and infusion timing in patients with advanced urothelial carcinoma (UC) are unclear.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed data from patients with advanced UC who received avelumab, without progression to first-line platinum-based chemotherapy. Efficacy and safety were evaluated according to age (<70, ≥70 to <80, and ≥80 years), PS (0 and ≥1), and infusion time of the first dose (early and late).</p><p><strong>Results: </strong>Twenty-three patients were analyzed [age (<70 years, n=10; ≥70 to <80, n=8; ≥80, n=5; PS (PS0, n=20; PS≥1, n=3); timing (early, n=13; late, n=10)]. Rates of any-grade adverse events (AEs) and grade ≥2 AEs were not significantly influenced by age (<i>p</i>=0.748 and <i>p</i>=0.615, respectively), PS (<i>p</i>>0.999 and <i>p</i>=0.539), or timing (<i>p</i>=0.685 and <i>p</i>=0.618). The disease control rate was not significantly influenced by age (<i>p</i>=0.663), PS (<i>p</i>>0.178), or timing (<i>p</i>=0.417). Median progression-free survival (PFS) was not significantly influenced by age (<i>p</i>=0.979), PS (<i>p</i>=0.620), or timing (<i>p</i>=0.208). Median overall survival (OS) was not significantly influenced by age (<i>p</i>=0.354), PS (<i>p</i>=0.590), or timing (<i>p</i>=0.552). When patients were divided into two groups according to PFS ≥6 months, OS was significantly different between the PFS <6 months group and the ≥6 months group (<i>p</i>=0.016).</p><p><strong>Conclusion: </strong>The efficacy and safety of avelumab maintenance therapy was not significantly influenced by age, PS, or infusion timing, and PFS ≥6 months could be a surrogate marker for OS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"976-987"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical Selective Nerve Root Block: Three-dimensional Puncture Planning With Dyna-CT Is Superior to Conventional CT-guidance in an <i>Ex Vivo</i> Model.","authors":"Sebastian Schneider, Hans Ulrich Kerl, Miriam Freundt, Katrin E Herrmann, Christoph Groden, Máté E Maros, Sherif A Mohamed","doi":"10.21873/invivo.13875","DOIUrl":"10.21873/invivo.13875","url":null,"abstract":"<p><strong>Background/aim: </strong>Cervical selective nerve root block (CSNRB) is a widely used percutaneous procedure to diagnose and treat cervical radicular pain. The feasibility of a three-dimensional puncture planning and two-dimensional laser-guidance system has previously been shown in an <i>ex vivo</i> model. The purpose of this study was to further compare this technique to the conventional computed tomography (CT-)-guided approach.</p><p><strong>Materials and methods: </strong>Thirty CSNRBs were performed, each with Dyna-CT and the Syngo iGuide^® laser-guidance system (Artis Zee^® Ceiling, Siemens Medical Solutions, Erlangen, Germany), and with conventional CT-guidance (Somatom Volume Zoom, Siemens Healthcare, Erlangen, Germany) in an <i>ex vivo</i> lamb model. The number of puncture attempts, procedural planning time, puncture time, and trajectory length were evaluated and compared.</p><p><strong>Results: </strong>All 60 punctures were rated as successful. Significantly less puncture attempts were needed with Dyna-CT compared to conventional CT-guidance (<i>p</i><0.0001). Procedural planning time and puncture time were significantly shorter with Dyna-CT (<i>p</i> _plan.t<0.0001 and <i>p</i> _punc.t=0.0004) (median 77 s and 56 s, respectively) than with conventional CT-guidance (median 109 s and 159.5 s, respectively), There were no significant differences in trajectory length (Dyna-CT median 3.18 cm; conventional CT median 3.33 cm, <i>p</i>=0.651).</p><p><strong>Conclusion: </strong>Dyna-CT with Syngo iGuide^® laser-guidance is superior to conventional CT-guidance for CSNRB in an <i>ex vivo</i> model. It significantly shortens the overall procedure time by reducing planning time, puncture time, and puncture attempts.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"713-723"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Clinicopathological Features on Gastric Cancer Stage According to TNM Classification.","authors":"Oliwia Majewska, Radosław Pach, Paweł Brzewski, Jan Kulig, Piotr Kulig","doi":"10.21873/invivo.13916","DOIUrl":"10.21873/invivo.13916","url":null,"abstract":"<p><strong>Background/aim: </strong>TNM stage is crucial for patients with gastric cancer because curative resection and treatment are only possible in early TNM stages. Therefore, our objective was to assess the association of clinicopathological features with TNM stage in such patients.</p><p><strong>Patients and methods: </strong>The association of age, sex, tumor location and Lauren type with TNM stage was analyzed in 910 patients with gastric cancer.</p><p><strong>Results: </strong>Age, sex, and tumor location did not have any association with TNM stage in univariate nor multivariate analyses (<i>p</i>>0.05). However, compared to the diffuse and mixed types, the intestinal type (as defined by the Lauren classification) presented lower T stage of gastric cancer in the chi-squared test (<i>p</i><0.001) and this association was confirmed in the multinominal log normal model (<i>p</i>=0.001).</p><p><strong>Conclusion: </strong>The histological Lauren type of gastric cancer is associated with lower TNM T stage.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1112-1121"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy.","authors":"Hui-Fu Hsu, Ruei-Yang Hu, Jeng-Wei Lu, Dueng-Yuan Hueng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Hsiao-Chen Liu, Feng-Cheng Liu","doi":"10.21873/invivo.13923","DOIUrl":"10.21873/invivo.13923","url":null,"abstract":"<p><strong>Background/aim: </strong>Subdural hematomas (SDH), often caused by head trauma, are serious with high mortality and long-term complications. Studies show that molecular hydrogen has neuroprotective effects, such as reducing oxidative stress, inflammation, and cell death. It may also protect mitochondria, support cell function, and regulate immune responses, making it a promising new treatment option for SDH. However, more research is needed to confirm its effectiveness and create treatment guidelines.</p><p><strong>Case report: </strong>We present a 24-year-old man with SDH, along with a right-sided midline shift, uncal herniation, and dilated left pupil. Conventional treatments-craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy-were essential for stabilizing his condition. In addition, we administered hydrogen capsules as a novel adjunct therapy, beginning daily treatment immediately upon admission. While recovery was primarily due to standard interventions, hydrogen therapy appeared to enhance immune markers, particularly Treg and plasma cells, with no adverse effects. This case indicates that hydrogen therapy may serve as a beneficial addition to established SDH management methods.</p><p><strong>Conclusion: </strong>This case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift. Conventional therapies, including craniectomy, hyperbaric oxygen, therapeutic hypothermia, and stem cell therapy, were vital to the patient's recovery, but hydrogen therapy may have contributed by modulating immune responses, particularly Treg and plasma cell activity. While these findings are encouraging, further research is necessary to confirm hydrogen therapy's benefits and its role alongside traditional neurocritical care treatments.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1190-1199"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic Mixed Acinar-neuroendocrine Carcinoma in a Patient With a Germline <i>PTEN</i> Variant: A Case Report and Genomic Literature Review.","authors":"Yosuke Saito, Shuhei Suzuki, Tomomi Sanomachi, Kaho Kato, Hiroya Otake, Yuko Nishise, Yuta Yamada, Koki Saito, Koshi Takahashi, Ryosuke Kumanishi, Tadahisa Fukui, Takashi Yoshioka","doi":"10.21873/invivo.13921","DOIUrl":"10.21873/invivo.13921","url":null,"abstract":"<p><strong>Background/aim: </strong>Cowden syndrome (CS)/PTEN hamartoma tumor syndrome (PHTS) is a hereditary disorder caused by germline <i>PTEN</i> variants. While patients with CS/PHTS have increased risk of various cancers, pancreatic cancer is not typically associated with this syndrome. We report a rare case of pancreatic mixed acinar-neuroendocrine carcinoma in a patient with a germline <i>PTEN</i> variant, aiming to understand its molecular characteristics and clinical implications.</p><p><strong>Case report: </strong>A male in his late 40s presented with pancreatic cancer and hepatic metastases. His medical history included thyroid cancer and familial gastrointestinal malignancies. Liver biopsy revealed mixed acinar-endocrine carcinoma. Cancer genome profiling identified pathogenic variants in <i>GNAS</i> and <i>TP53</i>, along with a germline <i>PTEN</i> variant (V201fs*1), leading to a diagnosis of CS. Notably, <i>KRAS</i> mutations, commonly found in pancreatic cancer, were absent. The patient showed extreme resistance to multiple chemotherapy regimens, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and cisplatin plus etoposide, resulting in rapid clinical decline.</p><p><strong>Conclusion: </strong>This case highlights a rare presentation of pancreatic cancer in CS/PHTS with distinct molecular and histological features. The absence of <i>KRAS</i> mutation and presence of germline <i>PTEN</i> variant may have contributed to the aggressive clinical course and treatment resistance. These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1173-1181"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imipramine-induced Apoptosis and Metastasis Inhibition in Human Bladder Cancer T24 Cells Through EGFR/ERK/NF-κB Pathway Suppression.","authors":"Wei-Shu Wang, Yu-Chang Liu, Tsai-Lin Lo, Fei-Ting Hsu, Chih-Hung Chiang","doi":"10.21873/invivo.13871","DOIUrl":"10.21873/invivo.13871","url":null,"abstract":"<p><strong>Background/aim: </strong>Bladder cancer is a prevalent malignancy, ranging from superficial forms to more aggressive types that invade the muscle and require extensive treatment. Imipramine, traditionally used as an antidepressant, has shown potential as an anti-cancer agent.</p><p><strong>Materials and methods: </strong>In this study, human bladder cancer T24 cells were treated with varying concentrations of imipramine to evaluate its cytotoxic and apoptotic effects.</p><p><strong>Results: </strong>Imipramine induced cytotoxicity in a dose-dependent manner, significantly increasing apoptosis as shown by Annexin-V/PI staining and TUNEL assay. The drug also up-regulated cleaved caspase-3 and down-regulated the anti-apoptotic factor XIAP. Moreover, imipramine activated both extrinsic/intrinsic apoptotic pathways, evidenced by the increased expression of Fas, FasL, cleaved caspase-8, and cleaved caspase-9, along with mitochondrial dysfunction and ROS production. Imipramine inhibited the migration and invasion of bladder cancer cells, likely through the down-regulation of metastasis-related proteins and suppression of the EGFR/ERK/NF-[Formula: see text]B signaling pathway.</p><p><strong>Conclusion: </strong>Imipramine could be a promising therapeutic agent for bladder cancer.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"669-682"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Claudin 18.2 Is Not a Promising Biomarker for Targeted Immunotherapy in Prostatic Cancers.","authors":"Jina Baek, Young Ran Shim, Mi-Jin Gu","doi":"10.21873/invivo.13884","DOIUrl":"10.21873/invivo.13884","url":null,"abstract":"<p><strong>Background/aim: </strong>Claudin 18.2 (CLDN18.2) has emerged as a highly selective biomarker and its abnormal expression has been reported in various primary malignant tumors. Recently, CLDN18.2 has gained attention as both a prognostic biomarker and a potential therapeutic target in gastric and gastroesophageal junction cancer. The purpose of this study was to investigate CLDN18.2 expression in a large cohort of 168 prostate cancer (PC) tissues, assess its correlation with clinicopathological factors, and evaluate its potential as a therapeutic target for anti-CLDN18.2 therapy.</p><p><strong>Materials and methods: </strong>Immunohistochemical staining was conducted using an approved diagnostic CLDN18.2 immunohistochemistry protocol (Ventana, 43-14A clone). Interpretation was carried out following the general rules for staining evaluation.</p><p><strong>Results: </strong>Non-neoplastic gastric mucosa, used as a positive control for CLDN18.2 immunostaining, exhibited strong membranous staining. In contrast, no CLDN18.2 expression was detected in normal ductal and acinar cells of prostate tissue, nor in any of the 168 variable PC tissues.</p><p><strong>Conclusion: </strong>CLDN18.2 is not expressed in normal prostate tissue or PC, suggesting that it is unlikely to serve as a prognostic marker or a potential target for immunotherapy in PC.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"819-823"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}